| Trial ID: | L3279 |
| Source ID: | NCT01225939
|
| Associated Drug: |
Azd8329
|
| Title: |
A Study Conducted Over 3 Periods to Look at the Drug in the Body
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: AZD8329|DRUG: AZD8329
|
| Outcome Measures: |
Primary: Compare the pharmacokinetics (Cmax and AUC) of the oral solution and the oral solid formulation of AZD8329., Information will be collected during 48h after each dose. | Secondary: Explore the effect of food on the pharmacokinetics (Tmax, T1/2 and CL/F) of AZD8329 oral solid formulation., Information will be collected during 48h after dose.|Investigate the safety and tolerability of AZD8329 administered as two different oral formulations.(Safety variables: Adverse events, Vital Signs, Clinical chemistry, Electrocardiogram (p ECG)), Adverse event will be collected from first dose to last visit . Clinical chemistry, Vital Signs and pECG's will be collected at all 5 visits
|
| Sponsor/Collaborators: |
Sponsor: AstraZeneca
|
| Gender: |
MALE
|
| Age: |
ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
18
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2010-11
|
| Completion Date: |
2010-12
|
| Results First Posted: |
|
| Last Update Posted: |
2011-03-02
|
| Locations: |
Research Site, London Bridge, United Kingdom
|
| URL: |
https://clinicaltrials.gov/show/NCT01225939
|
